Serum Small Proline-Rich Protein 2A (SPRR2A) Is a Noninvasive Biomarker in Gastric Cancer

Figure 2

Receiver operating characteristic (ROC) curves of serum SPRR2A and CEA levels considered separately and combined for predicting gastric cancer or gastritis. (a) A serum SPRR2A concentration yielded an AUC of 0.851 (–0.916), with 75.7% sensitivity and 74.5% specificity for discriminating GC patients from healthy people. A serum CEA concentration yielded an AUC of 0.743 (–0.832), with 23% sensitivity and 98% specificity. The AUC for the serum SPRR2A concentration combined with the CEA concentration was 0.876 (–0.935), with 79.7% sensitivity and 78.7% specificity. (b) Similarly, serum SPRR2A discriminated GC patients from gastritis patients with an AUC of 0.820 (–0.899), with 90.5% sensitivity and 61.7% specificity. Serum CEA yielded an AUC of 0.763 (–0.850), with 23% sensitivity and 97.9% specificity. The AUC for the serum SPRR2A concentration combined with the CEA concentration was 0.848 (–0.919), with 87.8% sensitivity and 68.1% specificity. (c) The AUC for serum SPRR2A was 0.877 (95% CI: 0.793–0.960) with 87.0% sensitivity and 70.2% specificity for discriminating stage III and IV patients from healthy people. The AUC for serum SPRR2A was 0.780 (95% CI: 0.669–0.891), with 69.6% sensitivity and 68.1% specificity for stage I and II patients.

(a)

(b)

(c)